Myeloid-associated antigen expression lacks prognostic value in childhood
acute lymphoblastic leukemia treated with intensive multiagent chemotherapy
CH Pui, FG Behm, B Singh, GK Rivera, MJ Schell, WM Roberts, WM Crist and J Mirro
Department of Hematology-Oncology, St Jude Children's Research Hospital,
Memphis, TN 38101.
Frequency and clinical significance of myeloid-associated antigen
expression in blast cells were assessed in 372 consecutive children with
acute lymphoblastic leukemia (ALL). A comprehensive panel of myeloid
monoclonal antibodies representing seven cluster groups showed
myeloid-associated antigen expression in 61 cases (16.4%), 18 of which
expressed two or more antigens. The antigens expressed comprised CD11b
(8.9% of the total series), CD13 (6.5%), CD33 (3.2%), CD36 (1.9%), CD15
(1.6%), CD14 (1.3%), and CDw12 (1.1%). No significant associations were
found between myeloid-associated antigen expression and the presence of
known adverse prognostic features (eg, higher leukocyte count, nonwhite
race, older age). Myeloid-associated antigen expression had no effect on
remission induction or event-free survival for the 267 children who had
been treated with the same combination of chemotherapeutic agents (P =
.34). Thus, blast cell expression of myeloid-associated antigens in
childhood ALL appears to lack prognostic value in the context of
contemporary intensive chemotherapy.
Volume 75,
Issue 1,
pp. 198-202,
01/01/1990
Copyright © 1990 by The American Society of Hematology
